Daiichi Sankyo Company, Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DSNKY research report →
Price Chart
About the company
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Its extensive and diverse portfolio features numerous key pharmaceutical offerings: Oncology: This includes trastuzumab deruxtecan (an anti-HER2 antibody-drug conjugate for cancer treatment), gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen, an anti-breast cancer agent. Cardiovascular and Metabolic Health: The company provides teneligliptin and a combination of teneligliptin/canagliflozin for managing type 2 diabetes mellitus, along with colesevelam for both hypercholesterolemia and type 2 diabetes.
- CEO
- Hiroyuki Okuzawa
- IPO
- 2008
- Employees
- 20,171
- HQ
- Tokyo, TY, JP
Get TickerSpark's AI analysis on DSNKY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.89B
- P/E
- 19.87
- Fwd P/E
- 0.12
- PEG
- -1.24
- P/S
- 2.15
- P/B
- 2.81
- EV/EBITDA
- 14.06
- Div Yield
- 3.39%
- Gross Margin
- 68.47%
- Op Margin
- 8.83%
- Net Margin
- 10.93%
- ROE
- 14.44%
- ROIC
- 5.71%
Latest fiscal year · YoY change
- Revenue
- $2.25T+19.3%
- Gross Profit
- $1.54T+4.8%
- Op Income
- $219.81B
- Net Income
- $275.55B-6.8%
- EPS
- $148.60-4.7%
- OCF Growth
- +52.9%
- FCF Growth
- +59.9%
- 52W High
- $27.50
- 52W Low
- $14.98
- 50D MA
- $17.78
- 200D MA
- $17.99
- Beta
- 0.14
- RSI (14)
- 37
- Avg Volume
- 131.44K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the DSNKY Q1 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 100.0%
- Shares Outstanding
- 1.82B
- Float Shares
- 1.82B
Congressional trading
Senate and House stock disclosures for DSNKY, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Held by 5 ETFs
Biggest fund positions in DSNKY by dollar value.
Our DSNKY coverage
Recent articles, reports, and earnings notes.
No research on DSNKY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DSNKY report →Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
seekingalpha.com · Oct 6
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
reuters.com · Oct 2
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
reuters.com · Sep 25
Malaysia's IHH's unit appeals Tokyo court's rejection of Daiichi Sankyo damages claim
reuters.com · Sep 24
Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up on Analyst Upgrade
defenseworld.net · Sep 24
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk
businesswire.com · Aug 28
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization
businesswire.com · Aug 24
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
businesswire.com · Aug 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.